Table 1 Baseline patients’ characteristics by BMI category
Characteristic | Total (n = 82) | BMI (kg/m2) | P value | ||
|---|---|---|---|---|---|
<25 (n = 21) | 25–29.9 (n = 34) | ≥ 30 (n = 27) | |||
Age (years) | |||||
Median (range) | 47.5 (24–74) | 41 (24–71) | 46 (28–74) | 50 (36–68) | 0.014 |
ECOG-PS scale | n% | ||||
0 | 8 (9.76) | 2 (9.52) | 2 (5.88) | 4 (14.81) | 0.108 |
1 | 60 (73.17) | 13 (61.90) | 30 (88.23) | 17 (62.96) | |
2 | 14 (17.07) | 6 (28.57) | 2 (5.88) | 6 (22.22) | |
No. of metastatic | |||||
1 site | 40 (48.78) | 8 (38.09) | 15 (44.11) | 17 (62.96) | 0.180 |
≥ 2 sites | 42 (51.22) | 13 (61.90) | 19 (55.88) | 10 (37.04) | |
HER2 | |||||
HER2+ | 56 (68.29) | 10 (47.62) | 25 (73.52) | 21 (77.77) | 0.064 |
HER2− | 22 (26.82) | 10 (47.62) | 6 (17.64) | 6 (22.22) | |
Unknown | 4 (4.88) | 1 (4.76) | 3 (8.82) | 0 (0) | |
Hormone receptors | |||||
ER+PR+ | 27 (32.92) | 8 (38.09) | 13 (38.23) | 6 (22.22) | 0.613 |
ER−PR− | 39 (47.56) | 8 (38.09) | 14 (41.17) | 17 (62.96) | |
ER+PR− | 6 (7.31) | 2 (9.52) | 2 (5.88) | 2 (7.41) | |
ER−PR+ | 6 (7.31) | 2 (9.52) | 2 (5.88) | 2 (7.41) | |
Unknown | 4 (4.88) | 1 (4.76) | 3 (8.82) | 0 (0) | |
Chemotherapy lines | |||||
1st line | 37 (45.12) | 11 (52.38) | 15 (44.11) | 11 (40.74) | 0.836 |
2nd line | 36 (43.90) | 7 (33.33) | 16 (47.05) | 13 (48.14) | |
≥ 3rd line | 9 (10.98) | 3 (14.28) | 3 (8.82) | 3 (11.11) | |
Other medications | |||||
Statins | 41 (50) | 10 (47.62) | 15 (44.11) | 16 (59.26) | |
Metastatic sites | (n = 129) sites | (n = 35) | (n = 55) | (n = 39) | |
Bone | 39 (30.23) | 12 (34.29) | 16 (29.09) | 11 (28.21) | 0.169 |
Visceral | 61 (47.29) | 18 (51.43) | 29 (52.73) | 14 (35.90) | |
Soft tissues | 29 (22.48) | 5 (14.29) | 10 (18.18) | 14 (35.90) | |